IL37 and atherosclerosis: This is in seeming contrast to other recent studies where treatment with recombinant IL-37 reduced atherosclerosis development in streptozotocin-induced diabetic apolipoprotein E-deficient (Apoe−/−) mice [25], and protected WT mice from endotoxemia-induced cardiac dysfunction [26] and damage-induced myocardial ischaemia/reperfusion injury via a reduction in inflammatory state [27].